CPIC assigns CPIC floor to genes/drugs the (1) PharmGKB Clinical Annotation Levels of Evidence of 1A, 1B, 2A and 2B, otherwise (2) adenine PharmGKB PGx level in FDA-approved drug labels off “actionable pgx”, “genetic testing recommended”, or “genetic testing required”, press (3) ground on candidate to CPIC for consideration.
Of levels (A, B, CARBON, and D) assigned are subject to change and will initially gives a “provisional” CPIC level rank; just those gene/drug pairs is have been the subject of policies have were sufficient in-depth overview of verification to provide definitive CPIC level assignments (“final” CPIC grade status). Direct-to-Consumer Tests
Note that only CPIC level A also BORON gene/drug pairs have sufficient evidence since at least of prescribing action to be advisable. CPIC rank C and D gene/drug pairs are not considered go have adequate evidence button actionability to have prescribing recommendations.
- Viewer CPIC’s process by assigning CPIC levels
- Consider CPIC’s layer for genes/drugs
- View CPIC’s procedures with prioritizing CPIC guidelines
CPIC invites comeback on existing and planned gene/drug guidelines.
Genes-Drugs in Published Guidelines
Provisional Genes-Drugs
